Skandinaviska Enskilda Banken (SEB)’s Avanos Medical AVNS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-45,600
Closed -$1.02M 804
2023
Q4
$1.02M Hold
45,600
0.01% 694
2023
Q3
$922K Sell
45,600
-9,400
-17% -$213K 0.01% 687
2023
Q2
$1.41M Buy
55,000
+7,600
+16% +$200K 0.01% 636
2023
Q1
$1.41M Buy
+47,400
New +$1.38M 0.01% 629
2022
Q3
Sell
-13,476
Closed -$368K 902
2022
Q2
$368K Sell
13,476
-2,568
-16% -$73.8K ﹤0.01% 846
2022
Q1
$537K Sell
16,044
-7,963
-33% -$256K ﹤0.01% 826
2021
Q4
$828K Hold
24,007
﹤0.01% 795
2021
Q3
$749K Buy
24,007
+22,426
+1,418% +$761K ﹤0.01% 829
2021
Q2
$58K Hold
1,581
﹤0.01% 1004
2021
Q1
$69K Hold
1,581
﹤0.01% 1065
2020
Q4
$73K Hold
1,581
﹤0.01% 1067
2020
Q3
$53K Hold
1,581
﹤0.01% 967
2020
Q2
$46K Hold
1,581
﹤0.01% 994
2020
Q1
$43K Hold
1,581
﹤0.01% 882
2019
Q4
$53K Hold
1,581
﹤0.01% 893
2019
Q3
$59K Hold
1,581
﹤0.01% 873
2019
Q2
$69K Buy
+1,581
New +$67.6K ﹤0.01% 801

Other funds holding AVNS

Skandinaviska Enskilda Banken (SEB)'s AVNS Position: Q1 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Avanos Medical (AVNS) in Q1 2024, closing a stake of 45,600 shares — an estimated $1.02M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in AVNS in Q2 2019 and held it in 17 quarters. The position peaked at $1.41M in Q1 2023. 261 funds tracked by Wall St. Rank hold AVNS as of Q1 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Avanos Medical position as of Q1 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 45,600 Avanos Medical shares in Q1 2024, an estimated $1.02M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Avanos Medical in Q2 2019 and held it in 17 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Avanos Medical position peaked at $1.41M in Q1 2023.
  • 261 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2024, filed 13 May 2024.